New drug tested for tough cancers
NCT ID NCT06336148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alfred Hospital, 55 Commercial Road, Site No: 201
Melbourne, Victoria, 3004, Australia
-
Southern Oncology Clinical Research Unit, Level 3, Mark Oliphant Building, 5 Laffer Drive, Site No: 202
Bedford Park, South Australia, 5042, Australia
-
UPMC Hillman Cancer Center, 5115 Centre Ave
Pittsburgh, Pennsylvania, 15232, United States
-
University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave.
Los Angeles, California, 90033, United States
-
Westmead Hospital, Cnr Hawkesbury Road and Darcy Road, Site No: 200
Westmead, New South Wales, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can your own immune cells beat advanced cancer?
- Can a Tumor's DNA guide better cancer care for kids?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new PET tracer reveal a key cancer target?